its all initial Euphoria, common in clinical stage biotech's and they officially call it regression to the mean , now we are in Reality Check / Slow Drag Phase, normally experienced CEOs would have experienced this and they would normally don't show these initial euphoria, but LC flaunting it is either she is seeing something in trials which she hasn't seen in her entire career, or to attract investments or she is not experienced enough.. I would say PH is not stupid to pay her that much, I would say its either awesome initial results or to attract investment..
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)